When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Multiple sclerosis

Last reviewed: 18 Aug 2025
Last updated: 21 Mar 2025

Summary

Definition

History and exam

Key diagnostic factors

  • visual disturbance in one eye
  • peculiar sensory phenomena
Full details

Other diagnostic factors

  • female sex
  • age 20-40 years
  • foot dragging or slapping
  • leg cramping
  • fatigue
  • urinary frequency
  • bowel dysfunction
  • spasticity/increased muscle tone
  • increased deep tendon reflexes
  • imbalance/incoordination
  • pale optic disk or noncorrectable visual loss
  • incorrect responses to Ishihara color blindness test plates
  • abnormal eye movements
Full details

Risk factors

  • female sex
  • family history of MS
  • northern latitude
  • genetic factors
  • smoking
  • vitamin D deficiency
  • autoimmune disease
  • Epstein-Barr virus
  • overweight/obesity in children and adolescents
Full details

Diagnostic tests

1st tests to order

  • MRI - brain
  • MRI - spinal cord
  • CBC
  • comprehensive metabolic panel
  • thyroid-stimulating hormone
  • vitamin B12
Full details

Pruebas diagnósticas que deben considerarse

  • antibody testing for neuromyelitis optica spectrum disorders (NMOSD)
  • cerebrospinal fluid evaluation
  • evoked potentials
Todos los datos

Algoritmo de tratamiento

Agudo

acute relapse affecting function

En curso

relapsing-remitting MS

secondary progressive MS

primary progressive MS

Colaboradores

Autores

Mary Alissa Willis, MD

Associate Professor and Chair

Department of Neurology

University of Mississippi Medical Center

Jackson

MS

Divulgaciones

MAW has been compensated for Speakers' Bureau participation with Alexion, Biogen, Bristol-Myers Squibb, Genzyme, and Genentech, and advisory board participation with Alexion, Biogen, Greenwich Biosciences, Genentech, and Horizon.

Agradecimientos

Dr Mary Alissa Willis would like to gratefully acknowledge Dr Lael A. Stone, a previous contributor to this topic. We have since been made aware that Dr Stone is deceased.

Revisores por pares

Alex Rae-Grant, MD

Project Leader for Neurology

Neurological Institute

Cleveland Clinic

Cleveland

OH

Divulgaciones

ARG declares that he has no competing interests.

Sarah A. Morrow, MD, FRCPC, MS

Associate Professor of Neurology

Department of Clinical Neurological Sciences

London Health Sciences Centre

University Hospital

Ontario

Canada

Divulgaciones

SAM declares that she has no competing interests.

Marcelo Kremenchutzky, MD

Director

The London Multiple Sclerosis Clinic

Associate Professor

Schulich School of Medicine

University of Western Ontario

Neurologist

Clinical Neurological Sciences Department

University Hospital

London Health Sciences Centre

Ontario

Canada

Divulgaciones

MK declares that he has no competing interests.

Abhijit Chaudhuri, DM, MD, PhD, FACP, FRCPGlasg, FRCPLond

Consultant Neurologist

Department of Neurology

Queen’s Hospital

Romford

UK

Divulgaciones

AC declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86.Texto completo  Resumen

Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021 Aug;20(8):653-670.Texto completo  Resumen

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. Resumen

Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol. 2006 Jun;19(3):248-54. Resumen

Filippi M, Rocca MA, Arnold DL, et al. Use of imaging in multiple sclerosis. In: Gilhus NE, Barnes MP, Brainin M, eds. European handbook of neurological management: volume 1, 2nd ed. Chichester, UK: Wiley-Blackwell; 2011:35-51.Texto completo

Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381.Texto completo  Resumen

Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015 Aug;15(4):273-9.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Multiple sclerosis images
  • Diferenciales

    • Myelopathy due to cervical spondylosis
    • Fibromyalgia
    • Postural orthostatic tachycardia syndrome with or without cervicogenic migraine
    Más Diferenciales
  • Guías de práctica clínica

    • Clinical guidance in neuropalliative care: an AAN position statement
    • Multiple sclerosis in adults: management
    Más Guías de práctica clínica
  • Folletos para el paciente

    Multiple sclerosis

    Multiple sclerosis: questions to ask your doctor

    Más Folletos para el paciente
  • Videos

    Diagnostic lumbar puncture in adults: animated demonstration

    Venepuncture and phlebotomy: animated demonstration

    Más vídeos
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad